JP7703448B2 - 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 - Google Patents

二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 Download PDF

Info

Publication number
JP7703448B2
JP7703448B2 JP2021549746A JP2021549746A JP7703448B2 JP 7703448 B2 JP7703448 B2 JP 7703448B2 JP 2021549746 A JP2021549746 A JP 2021549746A JP 2021549746 A JP2021549746 A JP 2021549746A JP 7703448 B2 JP7703448 B2 JP 7703448B2
Authority
JP
Japan
Prior art keywords
egfr
cancer
met
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521610A5 (cg-RX-API-DMAC10.html
JP2022521610A (ja
Inventor
ムーアズ，シェリ
ヴィジャヤラガヴァン，スムルシ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022521610A publication Critical patent/JP2022521610A/ja
Publication of JP2022521610A5 publication Critical patent/JP2022521610A5/ja
Priority to JP2024108371A priority Critical patent/JP2024153659A/ja
Priority to JP2025014414A priority patent/JP2025084739A/ja
Application granted granted Critical
Publication of JP7703448B2 publication Critical patent/JP7703448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021549746A 2019-02-26 2020-02-24 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 Active JP7703448B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024108371A JP2024153659A (ja) 2019-02-26 2024-07-04 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JP2025014414A JP2025084739A (ja) 2019-02-26 2025-01-30 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810716P 2019-02-26 2019-02-26
US62/810,716 2019-02-26
US201962930190P 2019-11-04 2019-11-04
US62/930,190 2019-11-04
PCT/IB2020/051559 WO2020174370A2 (en) 2019-02-26 2020-02-24 Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024108371A Division JP2024153659A (ja) 2019-02-26 2024-07-04 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JP2025014414A Division JP2025084739A (ja) 2019-02-26 2025-01-30 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化

Publications (3)

Publication Number Publication Date
JP2022521610A JP2022521610A (ja) 2022-04-11
JP2022521610A5 JP2022521610A5 (cg-RX-API-DMAC10.html) 2023-07-24
JP7703448B2 true JP7703448B2 (ja) 2025-07-07

Family

ID=72142314

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021549746A Active JP7703448B2 (ja) 2019-02-26 2020-02-24 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JP2024108371A Pending JP2024153659A (ja) 2019-02-26 2024-07-04 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JP2025014414A Pending JP2025084739A (ja) 2019-02-26 2025-01-30 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024108371A Pending JP2024153659A (ja) 2019-02-26 2024-07-04 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JP2025014414A Pending JP2025084739A (ja) 2019-02-26 2025-01-30 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化

Country Status (16)

Country Link
US (3) US11459391B2 (cg-RX-API-DMAC10.html)
EP (1) EP3931224A4 (cg-RX-API-DMAC10.html)
JP (3) JP7703448B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210132117A (cg-RX-API-DMAC10.html)
CN (1) CN113840842A (cg-RX-API-DMAC10.html)
AU (1) AU2020229467A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021016149A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131654A1 (cg-RX-API-DMAC10.html)
IL (1) IL285718A (cg-RX-API-DMAC10.html)
JO (1) JOP20210233A1 (cg-RX-API-DMAC10.html)
MA (1) MA55089A (cg-RX-API-DMAC10.html)
MX (1) MX2021010265A (cg-RX-API-DMAC10.html)
NZ (1) NZ778579A (cg-RX-API-DMAC10.html)
PH (1) PH12021552030A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108311RA (cg-RX-API-DMAC10.html)
WO (1) WO2020174370A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
JP7709384B2 (ja) * 2019-04-17 2025-07-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物
BR112021022828A2 (pt) * 2019-05-14 2022-04-12 Janssen Biotech Inc Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
EP4204455A4 (en) 2020-08-25 2024-10-16 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with egfr mutations
IL305700A (en) * 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
KR20240051145A (ko) * 2021-07-29 2024-04-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Kras 돌연변이 암의 치료를 위한 방법 및 조성물
KR102793991B1 (ko) 2021-10-06 2025-04-09 주식회사 엘지에너지솔루션 태양광 시스템과 연계하는 에너지 저장 시스템 및 에너지 저장 시스템의 제어 방법
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
AU2024236678A1 (en) * 2023-03-13 2025-10-30 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 ｃ－Ｍｅｔを標的とする多重特異性抗体
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
WO2026086844A1 (zh) * 2024-10-23 2026-04-30 正大天晴药业集团股份有限公司 靶向EGFR和c-Met的抗体药物偶联物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
WO2006086777A2 (en) 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
CA2601936C (en) 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CL2009000545A1 (es) * 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US8962808B2 (en) 2010-05-05 2015-02-24 The Research Foundation For The State University Of New York EGFR-related polypeptides and methods of use
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20170275367A1 (en) * 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
WO2015043614A1 (en) * 2013-09-26 2015-04-02 Biontech Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
WO2016081423A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
CN107427515B (zh) * 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US12595297B2 (en) * 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
EP3383435A4 (en) 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
WO2017200016A1 (ja) 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
LT3512882T (lt) 2016-09-14 2021-06-25 Merck Patent Gmbh Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
US11124575B2 (en) 2017-02-22 2021-09-21 University Of Saskatchewan EGFR-binding agents and uses thereof
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20210066819A (ko) 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20220143023A1 (en) 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
JP7709384B2 (ja) 2019-04-17 2025-07-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物
JP7822597B2 (ja) 2019-04-17 2026-03-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
TW202309094A (zh) * 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2016年，Vol. 76, No. 13，pp. 3942-3952

Also Published As

Publication number Publication date
JP2024153659A (ja) 2024-10-29
BR112021016149A2 (pt) 2021-10-13
US20230130600A1 (en) 2023-04-27
CA3131654A1 (en) 2020-09-03
WO2020174370A2 (en) 2020-09-03
US20200270351A1 (en) 2020-08-27
MX2021010265A (es) 2021-09-23
JOP20210233A1 (ar) 2023-01-30
CN113840842A (zh) 2021-12-24
WO2020174370A3 (en) 2020-12-03
SG11202108311RA (en) 2021-09-29
NZ778579A (en) 2026-03-27
PH12021552030A1 (en) 2022-08-15
JP2022521610A (ja) 2022-04-11
IL285718A (en) 2021-10-31
KR20210132117A (ko) 2021-11-03
US20250236675A1 (en) 2025-07-24
US11459391B2 (en) 2022-10-04
AU2020229467A1 (en) 2021-08-12
EP3931224A2 (en) 2022-01-05
JP2025084739A (ja) 2025-06-03
MA55089A (fr) 2022-01-05
US12215161B2 (en) 2025-02-04
EP3931224A4 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
US12215161B2 (en) Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
EP3938396A1 (en) Anti-icos antibodies for the treatment of cancer
US12528869B2 (en) Treatment of non-small cell lung cancer with EGFR mutations
JP2025500784A (ja) 結腸直腸癌を治療するためのアミバンタマブの使用
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
CN111051346A (zh) 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20260013482A (ko) 비-소세포 폐암(nsclc)의 치료 방법
IL323279A (en) Combination therapies with bispecific anti-EGFR/c-MET antibodies and anti-PD-1 antibodies
EP4716701A1 (en) Use of amivantamab to treat colorectal cancer
US20220298248A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
US20240228634A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
EA053157B1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ И СТРАТИФИКАЦИЯ ПАЦИЕНТОВ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К РЕЦЕПТОРАМ EGFR И c-MET
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250625

R150 Certificate of patent or registration of utility model

Ref document number: 7703448

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150